Effects of the P‐Selectin Antagonist Inclacumab on Myocardial Damage After Percutaneous Coronary Intervention According to Timing of Infusion: Insights From the SELECT‐ACS Trial

Effects of the P‐Selectin Antagonist Inclacumab on Myocardial Damage After Percutaneous Coronary Intervention According to Timing of Infusion: Insights From the SELECT‐ACS Trial

BackgroundThe Effects of the P‐Selectin Antagonist Inclacumab on Myocardial Damage After Percutaneous Coronary Intervention for Non‐ST‐Segment Elevation Myocardial Infarction (SELECT‐ACS) trial suggested beneficial effects of inclacumab, a monoclonal antibody directed against P‐selectin, on periproc...

Full description

Bibliographic Details
Main Authors: Barbara E. Stähli, Catherine Gebhard, Valérie Duchatelle, Daniel Cournoyer, Thibaut Petroni, Jean‐François Tanguay, Stephen Robb, Jessica Mann, Marie‐Claude Guertin, R. Scott Wright, Philippe L. L'Allier, Jean‐Claude Tardif
Format: Article
Language:English
Published: Wiley 2016-10-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
acute coronary syndrome
inflammation
myocardial infarction
percutaneous coronary intervention
thrombosis
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.116.004255

Internet

https://www.ahajournals.org/doi/10.1161/JAHA.116.004255

Similar Items